Danaher Corporation


SKU: DHR Category:


This is our first report on Danaher Corporation, a well-known manufacturer and provider of instruments and various other offerings to the medical, diagnostics, and environmental sectors. The company had a strong quarter and managed to surpass Wall Street expectations in terms of revenues as well as earnings. It delivered market share gains and strong price execution amid strong foreign exchange headwinds and an inflationary environment. Danaher is making strides in innovations related to gene therapy. It is a fact that genome medicines have shown double-digit-plus type growth for 11 straight quarters. The company has also been adding more tests to its portfolio such as the DxH900, a hematology testing device, the automation for mid-sized and smaller labs, DxA Fit, as well as early sepsis detection. The company is localizing in manufacturing, product management, and local R&D to be able to meet the needs of its customers in China. The capital allocation bias of the company stays towards M&A. We initiate coverage on the stock of Danaher Corporation with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!